MCID: TRN018
MIFTS: 64

Transitional Cell Carcinoma malady

Rare diseases, Cancer diseases, Nephrological diseases categories
Download this MalaCard

Summaries for Transitional Cell Carcinoma

About this section


Fully expand this MalaCard
Wikipedia:65 Transitional cell carcinoma (TCC, also urothelial cell carcinoma or UCC) is a type of cancer that... more...

MalaCards based summary: Transitional Cell Carcinoma, also known as transitional cell carcinoma of the urinary tract, is related to bladder transitional cell carcinoma and inverted papilloma. An important gene associated with Transitional Cell Carcinoma is ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), and among its related pathways are Transcriptional activation of cell cycle inhibitor p21 and GADD45 Pathway. The compounds topotecan and temozolomide have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and ovary, and related mouse phenotypes are pigmentation and hearing/vestibular/ear.

Disease Ontology:8 A carcinoma that derives from transitional epithelial cells.

Aliases & Classifications for Transitional Cell Carcinoma

About this section

Transitional Cell Carcinoma, Aliases & Descriptions:

Name: Transitional Cell Carcinoma 8 42 10
Transitional Cell Carcinoma of the Urinary Tract 8 62
Transitional Cell Neoplasm 8 62
Urothelial Cell Carcinoma 8 62
Transitional Cell Carcinoma Nos 8
 
Carcinoma, Transitional Cell 62
Carcinoma Transitional Cell 44
Transitional Cell Tumor 8
Transitional Carcinoma 8


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases, Cancer diseases
Anatomical: Nephrological diseases


External Ids:

Disease Ontology8 DOID:2671
NCIt39 C2930, C4030
MeSH34 D002295

Related Diseases for Transitional Cell Carcinoma

About this section

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 189)
idRelated DiseaseScoreTop Affiliating Genes
1bladder transitional cell carcinoma32.4IFI27, TP53
2inverted papilloma31.3KRT13, IFI27
3papilloma31.1KRT13, TP53, IFI27, CDKN1A
4bladder carcinoma30.9ERBB2, TP53, CDKN1A, CGB
5osteosarcoma30.5NOTCH1, TP53, CDKN1A, CGB
6lung cancer30.5EGFR, ERBB2, TP53, CDKN1A
7endometrial carcinoma30.2TP53, IFI27, EGFR, FGF3, ERBB2
8retinoblastoma30.1IFI27, EGFR, FGF3, TP53, CDKN1A, ERBB2
9prostate cancer29.8ERBB2, EGFR, CGB, CDKN1A, IFI27, PRSS8
10adenoma29.8CGB, CDKN1A, KRT13, FGF3, NR2F1, TP53
11adenocarcinoma29.5TP53, MMP10, PRSS8, IFI27, ERBB2, KRT13
12prostatitis10.8
13invasive bladder transitional cell carcinoma10.6
14sarcomatoid transitional cell carcinoma10.6
15prostate transitional cell carcinoma10.5
16ovary transitional cell carcinoma10.5
17endotheliitis10.5
18urethritis10.5
19tongue cancer10.5CDKN1A
20renal cell carcinoma10.5
21renal pelvis transitional cell carcinoma10.5
22superior vena cava syndrome10.5CGB
23urethra transitional cell carcinoma10.4
24horseshoe kidney10.4
25giant cell glioblastoma10.4EGFR
26esophageal cancer10.4TP53, EGFR
27biliary tract neoplasm10.4ERBB2, EGFR
28kidney pelvis sarcomatoid transitional cell carcinoma10.4
29collecting duct carcinoma10.4
30fallopian tube transitional cell carcinoma10.4
31bartholin's gland transitional cell carcinoma10.4
32ureter transitional cell carcinoma10.4
33urachal cyst10.4
34transitional cell carcinoma of the corpus uteri10.4
35li-fraumeni syndrome10.4TP53, CDKN1A
36malignant mixed mullerian tumor10.4TP53, ERBB2
37inflammatory breast carcinoma10.4EGFR, ERBB2
38breast cancer, invasive ductal10.4CDKN1A, TP53, ERBB2
39ductal carcinoma in situ10.4TP53, ERBB2, EGFR
40breast ductal carcinoma10.3ERBB2, EGFR, TP53
41bladder papillary transitional cell neoplasm10.3
42stomach cancer10.3TP53, ERBB2
43bladder carcinoma in situ10.3ERBB2, TP53, EGFR
44laryngeal benign neoplasm10.3TP53, EGFR, IFI27
45urethral diverticulum10.3
46papillary transitional carcinoma10.3
47endometrial transitional cell carcinoma10.3
48ureterocele10.3
49leukemoid reaction10.3
50hydronephrosis10.3

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to transitional cell carcinoma

Symptoms for Transitional Cell Carcinoma

About this section

Drugs & Therapeutics for Transitional Cell Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Transitional Cell Carcinoma

Search NIH Clinical Center for Transitional Cell Carcinoma

Genetic Tests for Transitional Cell Carcinoma

About this section

Anatomical Context for Transitional Cell Carcinoma

About this section

MalaCards organs/tissues related to Transitional Cell Carcinoma:

32
Kidney, Prostate, Ovary, Lymph node, Endothelial, Lung, Brain, Testes, Cervix, Bone, Breast, Testis, Monocytes, Bone marrow, Spinal cord, Heart, Colon, Adipocyte, Uterus, Dentritic cells, T cells, Neutrophil

Animal Models for Transitional Cell Carcinoma or affiliated genes

About this section

Publications for Transitional Cell Carcinoma

About this section

Articles related to Transitional Cell Carcinoma:

(show top 50)    (show all 1091)
idTitleAuthorsYear
1
Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. (24890092)
2014
2
Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review. (22511434)
2012
3
Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. (22759317)
2012
4
Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. (23018212)
2012
5
Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. (21346826)
2011
6
Ureterectomy and ureteral reimplatation for low-grade transitional cell carcinoma: is the laparoscopic approach feasible and effective? (21826883)
2011
7
Transitional cell carcinoma of the native urinary tract after kidney transplantation: recommendations following a long-term retrospective analysis. (21412138)
2011
8
Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. (19190765)
2009
9
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. (19773726)
2009
10
Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. (19033864)
2009
11
Transitional cell carcinoma in renal transplant recipients: a single center experience. (18184173)
2008
12
Transitional cell carcinoma of the urinary bladder: a clinicopathological study. (18946612)
2008
13
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. (18272914)
2008
14
Upper urinary tract transitional cell carcinoma. A 10-year experience. (18468339)
2008
15
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. (17293658)
2007
16
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. (17011058)
2006
17
Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. (15989448)
2005
18
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. (16361539)
2005
19
A case of transitional cell carcinoma of the renal pelvis with adenocarcinoma producing CEA and CA19-9]. (15518131)
2004
20
Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma. (15450303)
2004
21
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. (14685796)
2004
22
Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas. (14981907)
2003
23
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. (12796695)
2003
24
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. (12576464)
2003
25
Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. (11834417)
2002
26
p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. (11464113)
2001
27
Urinary cytokeratin 20 as a marker for transitional cell carcinoma. (10765100)
2000
28
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. (12840920)
2000
29
Screening for transitional cell carcinoma of the bladder with trophoblastic differentiation in Upper Galilee]. (10909500)
1998
30
Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma. (9818021)
1998
31
Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. (9477105)
1998
32
Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma. (10210109)
1998
33
Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. (9477184)
1997
34
Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma. (9373912)
1997
35
A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. (9264274)
1997
36
Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. (9037279)
1997
37
Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. (9275651)
1996
38
Expression of CD44 splice variants in human transitional cell carcinoma. (8740026)
1996
39
Overexpression of C-erbB3 in transitional cell carcinoma of the ovary]. (8745489)
1995
40
Transitional cell carcinoma of the renal pelvis with choriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. (8448745)
1993
41
The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. (8171764)
1993
42
Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. (1739130)
1992
43
Primary localized amyloidosis of the renal pelvis coexisting with transitional cell carcinoma: a case report. (1632328)
1992
44
c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder. (1364264)
1992
45
Transitional cell carcinoma in a urethral diverticulum. (1586346)
1992
46
Epidermal nevus with transitional cell carcinomas of the urinary tract. (1802914)
1991
47
Renal transitional cell carcinoma mimicking medullary sponge kidney. (2021801)
1991
48
ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-Guerin. (1710534)
1991
49
Correlation of the expression of A, B isoantigens with its precursor H antigen in transitional cell carcinoma and the clinical signification of the expression]. (2086062)
1990
50
Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa. (3121867)
1988

Variations for Transitional Cell Carcinoma

About this section

Expression for genes affiliated with Transitional Cell Carcinoma

About this section
Expression patterns in normal tissues for genes affiliated with Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for genes affiliated with Transitional Cell Carcinoma

About this section

Pathways related to Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 44)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.0CDKN1A, TP53
210.0CDKN1A, TP53
3
Show member pathways
10.0CDKN1A, TP53
410.0EGFR, ERBB2
5
Show member pathways
AhR pathway37
10.0EGFR, CDKN1A
610.0EGFR, NOTCH1
7
Show member pathways
DNA damage response (only ATM dependent)37
Wnt Signaling Pathway and Pluripotency37
9.8CDKN1A, ERBB2, TP53
8
Show member pathways
Development EGFR signaling via PIP360
Development PDGF signaling via MAPK cascades60
Apoptosis and survival Anti apoptotic action of membrane bound ESR160
Signaling of Hepatocyte Growth Factor Receptor37
Development EGFR signaling via small GTPases60
Development Neurotrophin family signaling60
Apoptosis and survival NGF signaling pathway60
Apoptosis and survival Role of CDK5 in neuronal death and survival60
9.8TP53, ERBB2, EGFR
99.8EGFR, ERBB2, TP53
10
Show member pathways
9.8TP53, ERBB2, EGFR
11
Show member pathways
9.8TP53, ERBB2, EGFR
12
Show member pathways
Translation Non genomic rapid action of Androgen Receptor60
9.8EGFR, CDKN1A, ERBB2
13
Show member pathways
9.8ERBB2, CDKN1A, EGFR
149.8EGFR, CDKN1A, TP53
159.8EGFR, CDKN1A, TP53
169.8TP53, CDKN1A, EGFR
179.8TP53, CDKN1A, EGFR
189.7RBX1, TP53
19
Show member pathways
9.6EGFR, CDKN1A, ERBB2, TP53
20
Show member pathways
ErbB receptor signaling network37
ErbB signaling pathway37
9.6EGFR, CDKN1A, ERBB2, TP53
219.6TP53, ERBB2, CDKN1A, EGFR
22
Show member pathways
Signal transduction PTEN pathway60
9.6TP53, ERBB2, CDKN1A, EGFR
239.6TP53, ERBB2, CDKN1A, EGFR
249.5TP53, RBX1, CDKN1A
25
Show member pathways
Cell cycle37
9.5TP53, RBX1, CDKN1A
26
Show member pathways
9.5TP53, ERBB2, EGFR, FGF3
27
Show member pathways
9.5FGF3, EGFR, CDKN1A, ERBB2
28
Show member pathways
9.5ERBB2, CDKN1A, EGFR, FGF3
29
Show member pathways
9.5ERBB2, CDKN1A, EGFR, FGF3
309.5TP53, CDKN1A, EGFR, FGF3
31
Show member pathways
9.5RBX1, NOTCH1, TP53
329.3TP53, ERBB2, NOTCH1, CDKN1A, EGFR
33
Show member pathways
9.3TP53, ERBB2, NOTCH1, CDKN1A, EGFR
34
Show member pathways
Signaling Pathways in Glioblastoma37
9.3TP53, ERBB2, CDKN1A, EGFR, FGF3
359.3FGF3, EGFR, CDKN1A, ERBB2, TP53
369.3ERBB2, RBX1, CDKN1A, EGFR
37
Show member pathways
Delta-Notch Signaling Pathway37
Notch Signaling Pathway37
9.2TP53, NOTCH1, RBX1, EGFR
38
Show member pathways
9.0FGF3, EGFR, RBX1, ERBB2, TP53
39
Show member pathways
9.0FGF3, EGFR, CDKN1A, RBX1, ERBB2
40
Show member pathways
9.0ERBB2, RBX1, CDKN1A, EGFR, FGF3
418.8FGF3, EGFR, CDKN1A, RBX1, ERBB2, TP53
428.7ERBB2, NOTCH1, RBX1, CDKN1A, EGFR, FGF3
43
Show member pathways
8.6TP53, MMP10, ERBB2, NOTCH1, CDKN1A, EGFR
44
Show member pathways
8.5TP53, ERBB2, NOTCH1, RBX1, CDKN1A, EGFR

Compounds for genes affiliated with Transitional Cell Carcinoma

About this section

Compounds related to Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 98)
idCompoundScoreTop Affiliating Genes
1topotecan44 1111.5EGFR
2temozolomide44 1111.4CDKN1A, TP53
3hrgbeta14410.2CDKN1A, EGFR, ERBB2
4p000484410.1CDKN1A, IFI27
5optimax4410.1CDKN1A, IFI27
6n-(4-hydroxyphenyl)retinamide4410.1ERBB2, TP53, CDKN1A
7pd1587804410.0EGFR, ERBB2
8jnj 28871063 hydrochloride6110.0EGFR, ERBB2
9taxane4410.0TP53, ERBB2, CDKN1A, EGFR
10suberoylanilide hydroxamic acid4410.0ERBB2, EGFR, TP53, CDKN1A
11oxaliplatin44 50 1112.0EGFR, TP53, ERBB2, CDKN1A
12flavopiridol44 1111.0ERBB2, CDKN1A, TP53, EGFR
13bortezomib44 50 1112.0CDKN1A, ERBB2, TP53, EGFR
14irinotecan44 50 1112.0TP53, ERBB2, CDKN1A, EGFR
15leucovorin44 50 1112.0ERBB2, EGFR, CGB
16geldanamycin44 50 61 1113.0ERBB2, EGFR, TP53, CDKN1A
17gemcitabine44 50 1112.0CDKN1A, TP53, ERBB2, EGFR
18hmba449.9IFI27, CDKN1A, TP53
19iressa619.9EGFR, ERBB2
20docetaxel44 50 61 1112.9ERBB2, EGFR, CDKN1A, TP53
21batimastat44 61 1111.9EGFR, MMP10, ERBB2
22egcg449.9CDKN1A, EGFR, TP53, ERBB2
23curcumin449.9EGFR, ERBB2, TP53, CDKN1A
24indole-3-carbinol449.9IFI27, CDKN1A, TP53
25sulindac44 1110.9TP53, IFI27, CDKN1A
265fluorouracil449.8EGFR, ERBB2, CDKN1A, TP53
27roscovitine449.7CDKN1A, IFI27, TP53
28gefitinib44 50 1111.7IFI27, ERBB2, CDKN1A, EGFR
29ag 490619.7EGFR, ERBB2
30resveratrol44 61 24 1112.7TP53, IFI27, CDKN1A, ERBB2
31adpribose449.7EGFR, CDKN1A, TP53, IFI27
32mg 13244 6110.7CDKN1A, IFI27, EGFR, TP53
33agar449.6ERBB2, CDKN1A, FGF3, EGFR
34thymidylate449.6ERBB2, IFI27, CDKN1A, EGFR, TP53
35n acetylcysteine449.5IFI27, TP53, CDKN1A, EGFR, ERBB2
36tamoxifen44 50 28 1112.5TP53, EGFR, CDKN1A, ERBB2, IFI27
37paclitaxel44 50 1111.5EGFR, ERBB2, CDKN1A, TP53, IFI27
38rapamycin449.5IFI27, ERBB2, EGFR, CDKN1A, NOTCH1
39genistein44 28 61 2 24 1114.4CDKN1A, NOTCH1, ERBB2, IFI27, EGFR
40retinoid449.4CDKN1A, IFI27, EGFR, TP53
41ly294002449.3TP53, IFI27, ERBB2, NOTCH1, CDKN1A, EGFR
42doxorubicin44 50 1111.3ERBB2, TP53, CDKN1A, NOTCH1, EGFR, IFI27
43cisplatin44 50 61 1112.2CGB, TP53, IFI27, ERBB2, CDKN1A, EGFR
44paraffin449.1EGFR, CDKN1A, ERBB2, IFI27, TP53, KRT13
45progesterone44 28 61 24 1113.0CGB, ERBB2, EGFR, NR2F1, IFI27, TP53
46serine448.7EGFR, MMP10, PRSS8, ERBB2, NOTCH1, CDKN1A
47estrogen448.7TP53, IFI27, NR2F1, NOTCH1, CDKN1A, EGFR
48vegf448.4FGF3, TP53, MMP10, IFI27, ERBB2, NOTCH1
49oligonucleotide448.2NR2F1, IFI27, MZF1, FGF3, MMP10, CDKN1A
50retinoic acid44 249.0MZF1, KRT13, NOTCH1, CDKN1A, EGFR, NR2F1

GO Terms for genes affiliated with Transitional Cell Carcinoma

About this section

Cellular components related to Transitional Cell Carcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1receptor complexGO:0432359.5EGFR, NOTCH1, ERBB2
2nucleoplasmGO:0056548.9CDKN1A, RBX1, NOTCH1, NR2F1, TP53

Biological processes related to Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1mitotic cell cycle arrestGO:07185010.2CDKN1A, TP53
2intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:04277110.0CDKN1A, TP53
3positive regulation of epithelial cell proliferationGO:05067910.0EGFR, NOTCH1, ERBB2
4cellular response to ionizing radiationGO:0714799.9CDKN1A, TP53
5cell cycle arrestGO:0070509.8CDKN1A, HEPACAM, TP53
6phosphatidylinositol-mediated signalingGO:0480159.8FGF3, EGFR, CDKN1A, ERBB2
7fibroblast growth factor receptor signaling pathwayGO:0085439.7ERBB2, CDKN1A, EGFR, FGF3
8Fc-epsilon receptor signaling pathwayGO:0380959.7ERBB2, CDKN1A, EGFR, FGF3
9positive regulation of reactive oxygen species metabolic processGO:20003799.7CDKN1A, TP53
10epidermal growth factor receptor signaling pathwayGO:0071739.7ERBB2, CDKN1A, EGFR, FGF3
11neurotrophin TRK receptor signaling pathwayGO:0480119.7ERBB2, CDKN1A, EGFR, FGF3
12Notch signaling pathwayGO:0072199.6TP53, NOTCH1, RBX1
13signal transductionGO:0071659.1NR2F1, ERBB2, EGFR, CGB, FGF3

Molecular functions related to Transitional Cell Carcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1epidermal growth factor-activated receptor activityGO:00500610.1EGFR, ERBB2
2transmembrane receptor protein tyrosine kinase activityGO:00471410.0EGFR, ERBB2
3receptor signaling protein tyrosine kinase activityGO:0047169.9ERBB2, EGFR
4protein phosphatase bindingGO:0199039.8EGFR, ERBB2, TP53
5protein bindingGO:0055156.7MZF1, TP53, PRSS8, NR2F1, ERBB2, NOTCH1

Products for genes affiliated with Transitional Cell Carcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Transitional Cell Carcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet